If the company meet the requirements they can apply to go mainboard. Hopefully by end of this year.

Heard from few remisers listing to mainboard will happen i around June. Hope it is true. And now our government give discount to list to mainboard. Must well take advantage. This company is making money.

@Tirara usually yes. Once announced it will go up.

Solarvest going to list on main market soon. Hold tight and buy more at dip.

This is exactly like Ewein. When he and Lim Guan Eng kena charged due to the Penang tunnel investigation the share dropped slowly from 0.80 to 0.25. This type of investigation take years. Good luck guys.

Thank god finally i can cabut. Bought before split and drop so much. Average down so many times still cannot run for almost 1 year. Finally!

Buy at dip before too late. Good company. No regrets...

@rocketstock
From what I understand they are not splitting shares. They will give free shares(if you have 10 lots you will get 5 lots free to be added into your mother share this 23/03) pls correct me. Thanks.

Don’t miss the chance. Buy more. Something is brewing.

Drop back. Aiyo..better run.

Must buy how many lots to get free warrants?

What is happening?

KUALA LUMPUR, 02 FEBRUARY 2021 - Ho Wah Genting Berhad ("HWGB" or the "Company") (Bursa Stock Code: 9601), through its wholly-owned subsidiary HWGB Biotech Sdn Bhd ("HWGB Biotech") has been successfully granted the Pharmacist's Poisons Licence (Type A License) from the Pharmaceutical Services Division of Ministry of Health Malaysia which enable the Company to import, store and deal generally by wholesale all controlled medicine (termed as poison according to Poisons Act Malaysia).

General Manager, Medical & Pharmaceutical Research of HWGB Biotech, Dr.Yaman Walid Kassab expressed: "We are delighted to have obtained the license which make us qualify to handle import and distribute our healthcare products in compliance with the MOH regulations. This license shows that we are committed in our healthcare related business and we believe that this license can bring a huge growth potential to HWGB as well".

"With the granted license, we believe that the consumer will be able to trust the product that we are going to distribute such as vaccines and controlled medicine. This is because only a pharmacist registered with the Pharmacy Board of Malaysia or a qualified pharmacist recognized by the state health directors of Sabah or Sarawak is able to hold for such license" he added.

Waiting to break 1.0 after 3rd party took over.

After all the big shots sold their shares on Wed but price still remain at 0.77. Hmm.. maybe it’s better luck for Opcom after he exit. Let’s have some faith. I wonder who is the biggest shareholder in opcom now?

2021 is year of 5G . Opcom sure will benefit from it.

Something is brewing. I’m sure insiders already know the good news. Tp 1.00 before Thursday.

Rm1 coming...

Definitely got good news coming. Just hold. Will go up more...

Tek Seng will fly tomorrow...

https://www.theedgemarkets.com/article/see-hup-sells-land-penang-tek-seng-rm4696m-cash?type=corporate

This counter so quiet.
Is it a good news that they classified as health care company?

Tek Seng still undervalued stocks. Be patient, it will fly back to 1.00.

@CHHu yes just temporary because they need to keep up with their mask and ppe production first priority due to Covid and busy with their factory expansion.

So tomorrow how? Up or down?

Naysayers go fly kite already. I still waiting to drop to 0.80. Congratulations to those who still hols tight. @ Zuraida tonight you can sleep well...

Who wants to sponsor me 0.80 100k lots? I want desperately...

Where is my 0.80?? Wakaka....

Hahaha....

Only panic selling will make the price drop more and sharks happy to collect. Do not sell cheap to those sharks.

Those who spread negative news here seems like they are all billionaires. They did not know exactly how Bintai is doing and they miss the boat at cheap price. They try to scare people off so that they can buy cheap. I didn’t see them when the price climb from 0.62-1.45. Now they are so happy to see the price drop. If you are not interested to invest in Bintai then I don’t understand why you are even here to scare people off. Pls if you hv nothing nice to say then pls be quiet. Don’t make people hv sleepless night.

Why worry? Bintai not necessary must sell or distribute in Malaysia la, Bintai will distribute for ASEAN which is even larger market than msia itself. Pls la you all... think carefully. Don’t panic sell, later regret.

When shares dropped a lot, all investors will say negative stuffs, swear at the company and etc. I think this is very natural and normal reaction for all human beings. Normal behaviour. To hold or not it is all up to your own belief. You are the one who put food on your own table. Don’t get influenced by negative thoughts. Think wisely. Cheers !

Our new normal is to wear mask, social distancing and hand sanitising even after the vaccines. There is no proof yet that vaccines can prevent you a 100% infected from Covid.

Reuters) - Britain will become the first country in the world on Tuesday to roll out the COVID-19 vaccine developed by Pfizer and BioNtech, initially making the shot available at 50 hospitals.

The country's National Health Service will give priority to vaccinating people over the age of 80, frontline healthcare workers and nursing home staff and residents.


Here is what people getting the vaccine should expect.

WHAT HAPPENS WHEN SOMEONE GETS THE VACCINE?

The vaccine, developed with new messenger RNA technology using a manufactured fragment of the coronavirus' genetic code, is injected into the arm. The immunization is given in two doses, three weeks apart, and has been shown in trials to protect up to 95% of recipients from contracting COVID-19.

Pfizer has said side effects in trial volunteers were mostly mild to moderate, and cleared up quickly. The most severe side effects occurred after the second dose: fatigue in 3.8% of volunteers and headache in 2%. Older adults tended to report fewer and milder adverse events.

WHAT KIND OF PROTECTION DOES IT GIVE?

The vaccine prevented COVID-19 illness seven days after the second injection - which is about a month after the first shot.

Clinical trials so far have not been designed to determine if an immunized person can still spread the coronavirus to someone else. Some vaccines, such as hepatitis A, do provide such protection - known as sterilizing immunity - but others do not. COVID-19 vaccine makers focused trials on determining whether the drug stopped people from getting ill.

It will also be several more months before it becomes clear how long the vaccination will protect someone from coronavirus infection.

"Until then, it is better to avoid the pub, and other in-person gatherings with many people," said Dr. Anita Shet, infectious disease specialist at Johns Hopkins Bloomberg School of Public Health.

DOES THE VACCINE MEAN BACK TO NORMAL LIFE?

Since there is no evidence that the immunization prevents transmission of the virus - and no vaccine is 100% effective - scientists call for continued vigilance, including mask-wearing, hand-washing and social distancing.

"As with all vaccines, it may work really great in certain patient subsets, but not as well in others ... Does that mean you are free to hop on a plane or have 30 people over at your house? Probably not," said Dr. Michelle Barron, senior medical director for infection prevention at Colorado's UCHealth.

She said vaccination campaigns are unlikely to reach "a critical mass" until next spring or early summer.

(Reporting by Deena Beasley, Editing by Peter Henderson and Aurora Ellis)

Khairy didn’t know what he is talking about la.. be patient guys, will rebound back.

This Khairy didn’t know what he is talking about la...

Year Ender 2020 – Who’s who among Bursa-listed companies in Covid-19 vaccine play
AMIR IMRAN HUSAIN SAFRI / 07 DEC 2020 / 11:00 H.
Year Ender 2020 – Who’s who among Bursa-listed companies in Covid-19 vaccine play
A vial labelled ‘Covid-19 Coronavirus Vaccine’ is held over dry ice in this illustration picture. – REUTERSPIX
PETALING JAYA: The ongoing Covid-19 pandemic has dictated the performance of the global economy for the majority of 2020. In the early days of the novel coronavirus outbreak, there were a number of companies that jumped on the glove-manufacturing bandwagon, and now with positive news on vaccine development, several more Bursa Malaysia-listed companies are entering the vaccine manufacturing and distribution business.

Making the list of Bursa-listed companies in the vaccine effort is Kanger International Bhd, which joined the foray in September via an agreement with Shenzhen Public Health Technology Co Ltd to secure a dealership/distributorship from China National Pharmaceutical Group Corp’s (Sinopharm) potential vaccine.

Since its initial announcement, the group has entered into two separate agreements with Zuellig Pharma Sdn Bhd and K-Star Sport Ltd for the distribution of Covid-19 vaccine in Malaysia and subsequently received no objections by the Science, Technology and Innovation Ministry (Mosti) for the purchase of vaccine for private sector use in the country.


Similarly, Metronic Global Bhd entered into a memorandum of agreement with Taiwan-listed pharmaceutical company, Medigen Vaccine Biologics Corp for its Covid-19 vaccine, via its subsidiary, Metronic Medicare Sdn Bhd.

Before the group can commence the distributorship, it has to secure a pharmaceutical good distribution practice certification with the National Pharmaceutical Regulatory Agency and register the product with the agency, which entails a full evaluation of the vaccine, including local clinical trials. It expects to submit the documents by 2022/2023.

From the vaccine, Metronic has projected an estimated gross profit of RM120 million to RM180 million based on a price assumption of US$50 per dose and an estimated industry wide gross margin of 20% to 30%.

Bintai Kinden Corp entered into a framework agreement for the development and commercialisation of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China with Chinese Center for Disease Control and Prevention (China CDC), Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co Ltd via its partner, Generex Biotechnology Corp in November.

Subsequently, Generex has signed a US$50 million licensing and development deal for the exclusive use of its vaccine platform technology for infectious disease and cancer in China and its territories.

Under the agreement , Bintai is granted exclusive rights to distribute, sell and commercialise the Covid-19 vaccine in Malaysia, Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, the Philippines, Singapore, Thailand and Vietnam. It also has the right of first refusal to commercially exploit the vaccine in New Zealand, Australia and the global halal market.

Ho Wah Genting has also ventured into vaccine play through its collaboration with US-based E-MO Biology Inc (EBI). In November, its vaccine received approval by the US Food & Drug Administration to begin phase IV clinical trials.

The group has also entered into a memorandum of understanding with China’s Xinkexian (Beijing) Biotechnology Co Ltd to appoint the latter as a non-exclusive manufacturer for the vaccine related to the Covid-19 virus, which is contingent on EBI’s successful completion of clinical trials.

DKSH Holdings (Malaysia) Bhd, too, is seen as a possible beneficiary of the vaccine development play, due to its long-term relationships with AstraZeneca and Pfizer, which are front runners in the global vaccine race. Given its established links with the two front runners, there is a probability that the group will be involved in its distribution when the vaccine becomes commercially available.

Similarly, government-linked counters, Pharmaniaga Bhd and Duopharma Biotech Bhd have been identified by the government as pharmaceutical players with the capacity to undertake fill-finish processing for any Covid-19 vaccine.

Given the scale of the pandemic, MIDF Research’s head of research Imran Yassin believes the vaccine will not be reduced to one or two types coming from one or two players.

“Here, we believe that it is a case of more is better. In terms of involvement, again we believe that there will not be one type of involvement which is the best,” he told SunBiz.

Imran opined that any involvement in the value chain will be critical as this is a health crisis, first and foremost.

Year Ender 2020 – Who’s who among Bursa-listed companies in Covid-19 vaccine play
AMIR IMRAN HUSAIN SAFRI / 07 DEC 2020 / 11:00 H.
Year Ender 2020 – Who’s who among Bursa-listed companies in Covid-19 vaccine play
A vial labelled ‘Covid-19 Coronavirus Vaccine’ is held over dry ice in this illustration picture. – REUTERSPIX
PETALING JAYA: The ongoing Covid-19 pandemic has dictated the performance of the global economy for the majority of 2020. In the early days of the novel coronavirus outbreak, there were a number of companies that jumped on the glove-manufacturing bandwagon, and now with positive news on vaccine development, several more Bursa Malaysia-listed companies are entering the vaccine manufacturing and distribution business.

Making the list of Bursa-listed companies in the vaccine effort is Kanger International Bhd, which joined the foray in September via an agreement with Shenzhen Public Health Technology Co Ltd to secure a dealership/distributorship from China National Pharmaceutical Group Corp’s (Sinopharm) potential vaccine.

Since its initial announcement, the group has entered into two separate agreements with Zuellig Pharma Sdn Bhd and K-Star Sport Ltd for the distribution of Covid-19 vaccine in Malaysia and subsequently received no objections by the Science, Technology and Innovation Ministry (Mosti) for the purchase of vaccine for private sector use in the country.


Similarly, Metronic Global Bhd entered into a memorandum of agreement with Taiwan-listed pharmaceutical company, Medigen Vaccine Biologics Corp for its Covid-19 vaccine, via its subsidiary, Metronic Medicare Sdn Bhd.

Before the group can commence the distributorship, it has to secure a pharmaceutical good distribution practice certification with the National Pharmaceutical Regulatory Agency and register the product with the agency, which entails a full evaluation of the vaccine, including local clinical trials. It expects to submit the documents by 2022/2023.

From the vaccine, Metronic has projected an estimated gross profit of RM120 million to RM180 million based on a price assumption of US$50 per dose and an estimated industry wide gross margin of 20% to 30%.

Bintai Kinden Corp entered into a framework agreement for the development and commercialisation of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China with Chinese Center for Disease Control and Prevention (China CDC), Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co Ltd via its partner, Generex Biotechnology Corp in November.

Subsequently, Generex has signed a US$50 million licensing and development deal for the exclusive use of its vaccine platform technology for infectious disease and cancer in China and its territories.

Under the agreement , Bintai is granted exclusive rights to distribute, sell and commercialise the Covid-19 vaccine in Malaysia, Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, the Philippines, Singapore, Thailand and Vietnam. It also has the right of first refusal to commercially exploit the vaccine in New Zealand, Australia and the global halal market.

Ho Wah Genting has also ventured into vaccine play through its collaboration with US-based E-MO Biology Inc (EBI). In November, its vaccine received approval by the US Food & Drug Administration to begin phase IV clinical trials.

The group has also entered into a memorandum of understanding with China’s Xinkexian (Beijing) Biotechnology Co Ltd to appoint the latter as a non-exclusive manufacturer for the vaccine related to the Covid-19 virus, which is contingent on EBI’s successful completion of clinical trials.

DKSH Holdings (Malaysia) Bhd, too, is seen as a possible beneficiary of the vaccine development play, due to its long-term relationships with AstraZeneca and Pfizer, which are front runners in the global vaccine race. Given its established links with the two front runners, there is a probability that the group will be involved in its distribution when the vaccine becomes commercially available.

Similarly, government-linked counters, Pharmaniaga Bhd and Duopharma Biotech Bhd have been identified by the government as pharmaceutical players with the capacity to undertake fill-finish processing for any Covid-19 vaccine.

Given the scale of the pandemic, MIDF Research’s head of research Imran Yassin believes the vaccine will not be reduced to one or two types coming from one or two players.

“Here, we believe that it is a case of more is better. In terms of involvement, again we believe that there will not be one type of involvement which is the best,” he told SunBiz.

Imran opined that any involvement in the value chain will be critical as this is a health crisis, first and foremost.

Today panic selling due to Khairy’s statements. All kecut and run. Eventually it will rebound again. Be patient.

Today vaccines team all gg. Tomorrow will rebound.

Yes careplus also drop like this and scared people out, after that fly uptrend nonstop. I regret I didn’t top up that time:((

I sold all my Solarvest. Now I scared too high to enter. Will wait. At the mean time i ran to Tek Seng first. Still undervalued.

Be patient guys... good counter. Will go up.

Hopefully Monday will cross 0.80 ...

Tek seng still undervalued. Still cheap to buy!

Yes pls sell to me. I will collect more.

Yes Tek Seng time to wake up. We still need mask and ppe. Is not the end of covid even if vaccine is out. We still need you.

Solution up first, second Bintai and third hwgb. Buy now before too late.

Hwgb still cheap... buy buy buy!